Clinical reference Biomarker Directory
Back to directory

Anticardiolipin antibody

Established

Anticardiolipin antibody is one of three tests used together to classify antiphospholipid syndrome.

Also known as Anticardiolipin antibody aCL
In plain language

This antibody is tested alongside two others to diagnose antiphospholipid syndrome, a clotting disorder. Newer 2023 criteria changed exactly how doctors weigh the different antibody results together.

Biomarker & context

Anticardiolipin antibodies target cardiolipin, a phospholipid, and are one of three antiphospholipid antibodies (with anti-β2GP1 and lupus anticoagulant) used to classify antiphospholipid syndrome (APS).

What it indicates

Medium-to-high titer IgG or IgM anticardiolipin, combined with a qualifying clinical event (thrombosis or pregnancy morbidity), supports an APS diagnosis; low titers or isolated positivity without clinical correlation are less specific.

Diagnosis & clinical testing

Measured via ELISA; the 2023 ACR/EULAR APS classification criteria revised how anticardiolipin, anti-β2GP1, and lupus anticoagulant are weighted together, changing diagnostic thresholds compared to older criteria.

Guiding treatment

Persistent, medium-to-high titer anticardiolipin positivity in a patient with prior thrombosis typically guides long-term anticoagulation therapy decisions and pregnancy management protocols.

Clinical significance

Requires a qualifying clinical thrombotic or pregnancy event alongside positive serology for diagnosis.

References
  1. 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.